Solanezumab does not slow cognitive decline in patients with Alzheimer’s disease
1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not slow cognitive decline as compared ...
Tag: Solanezumab
#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Solanezumab does not improve cognition or functioning in Alzheimer’s disease [EXPEDITION Trials]
Image: PD 1. Solanezumab did not improve cognition or functional ability in mild-to-moderate Alzheimer’s disease at week 80. 2. Solanezumab ...